Pax Labs is on a mission to take over the world. Okay that’s a bit drastic, but they certainly have their sights set on dominating the entire vaporizer industry, from herb vapes (PAX 1, PAX 2) to the cigarette market. Notice we didn’t say e-cig market…with Pax Labs recent lease of the Juul eCig, its clear they are making the hardest push yet into converting current smokers into vapers. The Juul delivers an experience like no other ecig ever has. The technology they have used to properly extract nicotine salts similar to that of an actual tobacco combustion experience…well its just like nothing else on the market. If you’re a cigarette smoker that hasn’t ever liked an eCig, try the Juul. It will change your mind in one puff.
2015 has seen two product launches from Pax Labs, and they look poised for more. Many medical companies are investigating vapes as a means of delivering many things from medicine to insulin, and there have been rumblings of a Pax Labs, FDA-approved, insulin device. Yesterday Pax Labs announced a round of series C funding, raising a total of 46.7 million. Per TechCrunch:
The company is receiving $46.7 million in Series C financing led by existing investors, including Tao Capital and Sand Hill Angels, with participation from Fidelity Management & Research Company, Sivia Capital, and many more.
The Pax 2 is selling well, and the Juul looks primed for success. Vitamin vapes? Protein vapes? Insulin vapes? Morphine vapes? We can’t wait to see what is in store. What could Pax Labs, who has sold over 500,000 units worldwide and generated huge sums of money need with such a large amount of funding?
Total world domination isn’t cheap.